Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia

Conditions:   Acute Lymphoblastic Leukemia, in Relapse;   Acute Lymphoblastic Leukemia With Failed Remission Intervention:   Drug: Bortezomib Sponsors:   Instituto do Cancer do Estado de São Paulo;   Libbs Farmacêutica LTDA Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials